Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy

Langer, Oded; Anyaegbunam, Akolisa; Brustman, Lois; Divon, Michael Y.

doi:10.1016/0002-9378(89)90361-x

Cited by 151 publications

(61 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this study are consistent with previous reports that minor abnormalities of glucose metabolism without GDM are a significant risk factor for fetal overgrowth (3,4,(6)(7)(8)19). The level of risk is related to gestational age at the onset of abnormal maternal glucose metabolism.…”

Section: Discussionsupporting

confidence: 92%

“…Another report (5) showed a positive association between 1-h glucose screening test values and birth weight. Women who had only one elevated value on an OGTT had macrosomic neonates significantly more often than those having normal glucose screens (6) and normal OGTT (7,8). These findings support the concept of a continuum of glucose abnormality and the thesis that an abnormal glucose challenge test (GCT) in pregnancy is a risk factor for LGA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test

Mello¹,

Parretti²,

Mecacci³

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate whether minor abnormalities of glucose metabolism without gestational diabetes are a risk factor for fetal overgrowth. Design: A sample of 1883 unselected white mother-infant pairs were screened for gestational diabetes using a 50 g 1-h oral glucose challenge test (GCT) in two periods of pregnancy: early (16-20 weeks) and late (26-30 weeks). Methods: The effects of risk factors (glucose metabolism, previous history of mothers, obesity, multiparity and age of mothers) were estimated using a multinomial logit model. Results: The level of risk was related to gestational age at the appearance of an abnormal GCT. Patients with an abnormal GCT in the early and late periods of pregnancy (Group 1) had a risk of delivering a large for gestational age (LGA) infant seven times higher than the control group (normal GCT in both periods), and patients with a normal GCT in the early period and an abnormal GCT in the late period (Group 2) showed a risk three times higher than the control group. Among the historical risk factors for LGA infants, such as maternal obesity, multiparity, previous gestational diabetes and previous delivery of an infant weighing 4000 g or more, only the latter was associated with fetal overgrowth with a risk level 4.7 higher than the control group. Group 1 patients had a significantly higher incidence of pregnancy-induced hypertension and preterm birth. There were no differences in the frequency of 5-min Apgar score <7 and metabolic complications among the infants of all groups. We found a significantly higher rate of shoulder dystocia in Group 1 infants than in infants in the other groups. Conclusions: Our results suggest that a positive GCT at 26-30 weeks is the most important risk factor for fetal overgrowth. This result was strongly enforced in patients who had also shown a positive early GCT at 16-20 weeks.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test

Mello¹,

Parretti²,

Mecacci³

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Pregnant women with OAV on a 100-g OGTT are connected to a higher frequency of adverse perinatal events when compared to a population with normal glucose tolerance [20,22]. The glycemic profile and characteristics of these pregnant women are similar to those of women with a diagnosis of traditional GDM.…”

Section: Discussionmentioning

confidence: 97%

Prognosis of Pregnant Women with One Abnormal Value on 75g OGTT

Kozuma¹,

Inoue

Horinouchi

et al. 2014

Kurume Med. J.

View full text Add to dashboard Cite

“…With regard to twostep testing, a systematic review in 2012 showed that this failed to detect ;26% of GDM cases (30). With regard to the "two abnormal values" rule, multiple epidemiologic studies have demonstrated that one abnormal value carries similar risks of pregnancy complications (31) and one randomized controlled trial (RCT) has demonstrated treatment benefits if such women are labeled as having GDM and treated accordingly (32).…”

Section: Knowledgementioning

confidence: 99%

Discovery, Knowledge, and Action—Diabetes in Pregnancy Across the Translational Spectrum: The 2016 Norbert Freinkel Award Lecture

McIntyre

2018

Diabetes Care

View full text Add to dashboard Cite

The Norbert Freinkel Award is given in memory of Norbert Freinkel, a dedicated and insightful investigator and gifted writer, to honor a researcher who has made outstanding contributions, including scientific publications and presentations, to the understanding and treatment of diabetes in pregnancy. H. David McIntyre, MD, FRACP, Director of Obstetric Medicine at Mater Health Services and Head of the Mater Clinical Unit at The University of Queensland in Brisbane, Australia, received the prestigious award at the American Diabetes Association's 76th Scientific Sessions, 10–14 June 2016, in New Orleans, LA. He presented the Norbert Freinkel Award Lecture, “Discovery, Knowledge, and Action—Diabetes in Pregnancy Across the Translational Spectrum,” on Saturday, 11 June 2016.

show abstract

Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy

Cited by 151 publications

References 9 publications

Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test

Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test

Prognosis of Pregnant Women with One Abnormal Value on 75g OGTT

Discovery, Knowledge, and Action—Diabetes in Pregnancy Across the Translational Spectrum: The 2016 Norbert Freinkel Award Lecture

Contact Info

Product

Resources

About